Health In Tech (NASDAQ:HIT - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Saturday.
Separately, Maxim Group upgraded Health In Tech to a "strong-buy" rating and set a $2.50 target price on the stock in a report on Thursday, June 26th.
Check Out Our Latest Stock Report on Health In Tech
Health In Tech Stock Performance
NASDAQ:HIT opened at $1.13 on Friday. Health In Tech has a 12-month low of $0.51 and a 12-month high of $7.59. The business has a fifty day moving average of $0.72.
Health In Tech (NASDAQ:HIT - Get Free Report) last posted its quarterly earnings results on Monday, April 14th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.01). The firm had revenue of $8.02 million during the quarter, compared to analyst estimates of $6.87 million.
Hedge Funds Weigh In On Health In Tech
Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in Health In Tech during the first quarter worth approximately $48,000. Cubist Systematic Strategies LLC acquired a new position in Health In Tech during the first quarter worth approximately $41,000. Arete Wealth Advisors LLC acquired a new position in Health In Tech during the first quarter worth approximately $47,000. Finally, XTX Topco Ltd acquired a new position in Health In Tech during the first quarter worth approximately $59,000.
About Health In Tech
(
Get Free Report)
Health in Tech, Inc engages in the provision of insurance technology platforms which offer a marketplace of processes in the healthcare industry. Its services include Stone Mountain Risk, eDIYBS, HI Card, HI Performance Network, and Ancillary Products. The company was founded by Tim Johnson in 2014 and is headquartered in Stuart, FL.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Health In Tech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health In Tech wasn't on the list.
While Health In Tech currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
